Global HIV Vaccine Market & Clinical Trial Outlook 2022
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
“Global HIV Vaccine Market & Clinical Trial Outlook 2022” recent report published by Kuick Research analyzes various multiple clinical and non-clinical aspects related to development of HIV vaccine worldwide. Currently there is no particular vaccine available for the treatment of HIV across the globe. There are multiple vaccines in clinical trials for the treatment and the prevention of HIV. This report gives comprehensive clinical insight on the 65 HIV Vaccines in clinical trials and analyzes all clinical parameters involved in the development of HIV Vaccine. Report analyzes multiple approaches in the development of the HIV vaccine and lists decisive factors responsible for the commercialization of HIV vaccines.
Worldwide, around 35 Million people are currently infected with the HIV and about 30 Million people died because of the AIDS infection since the beginning of the epidemic. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways of immune system which needs to respond against the HIV infection.
Vaccines are among the most powerful and cost-effective disease prevention tools. A vaccine that could prevent the HIV infection or stop the development of the disease would greatly support in the fight against the AIDS disease. Vaccines have been crucial in worldwide smallpox elimination efforts, have nearly eliminated polio and have drastically reduced the incidence of infectious diseases like measles and pertussis in the US. However, the question is arising that whether HIV vaccine should be developed for a single strain or it should be designed for varied strain structures. The whole aim is to provide the better medication for the eradication of the virus by any means.
There are also questions about how an HIV vaccine would protect the individuals and the vaccine might not be able to actually prevent the infection, but could stop or delay progression to disease, or simply reduce the infectiousness of people who do become infected with HIV. HIV prevention education and counseling are important constituents of vaccine programs and after the release of a vaccine; there will be an ongoing need for effective behavioral prevention programs.
The successful development of a preventive HIV vaccine will almost positively depend upon the involvement of both the private and public sectors from around the world. Currently, no one government or company has the resources and encouragement to take on the challenge for developing an HIV vaccine alone. Within the public sector, the development of an HIV vaccine is important for a number of different agencies, which includes the concerns in health, economic development, and international development.
“Global HIV Vaccine Market & Clinical Trial Outlook 2022” Report Highlights:
“Global HIV Vaccine Market & Clinical Trial Outlook 2022” recent report published by Kuick Research analyzes various multiple clinical and non-clinical aspects related to development of HIV vaccine worldwide. Currently there is no particular vaccine available for the treatment of HIV across the globe. There are multiple vaccines in clinical trials for the treatment and the prevention of HIV. This report gives comprehensive clinical insight on the 65 HIV Vaccines in clinical trials and analyzes all clinical parameters involved in the development of HIV Vaccine. Report analyzes multiple approaches in the development of the HIV vaccine and lists decisive factors responsible for the commercialization of HIV vaccines.
Worldwide, around 35 Million people are currently infected with the HIV and about 30 Million people died because of the AIDS infection since the beginning of the epidemic. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways of immune system which needs to respond against the HIV infection.
Vaccines are among the most powerful and cost-effective disease prevention tools. A vaccine that could prevent the HIV infection or stop the development of the disease would greatly support in the fight against the AIDS disease. Vaccines have been crucial in worldwide smallpox elimination efforts, have nearly eliminated polio and have drastically reduced the incidence of infectious diseases like measles and pertussis in the US. However, the question is arising that whether HIV vaccine should be developed for a single strain or it should be designed for varied strain structures. The whole aim is to provide the better medication for the eradication of the virus by any means.
There are also questions about how an HIV vaccine would protect the individuals and the vaccine might not be able to actually prevent the infection, but could stop or delay progression to disease, or simply reduce the infectiousness of people who do become infected with HIV. HIV prevention education and counseling are important constituents of vaccine programs and after the release of a vaccine; there will be an ongoing need for effective behavioral prevention programs.
The successful development of a preventive HIV vaccine will almost positively depend upon the involvement of both the private and public sectors from around the world. Currently, no one government or company has the resources and encouragement to take on the challenge for developing an HIV vaccine alone. Within the public sector, the development of an HIV vaccine is important for a number of different agencies, which includes the concerns in health, economic development, and international development.
“Global HIV Vaccine Market & Clinical Trial Outlook 2022” Report Highlights:
- Introduction to Human Immunodeficiency Virus (HIV) Vaccines
- HIV Vaccine Development Process
- Modified Approaches for HIV Vaccine Development
- HIV Drugs Taxonomy & Resistance
- Decisive Factors for Commercialization of HIV Vaccines
- Global HIV Vaccine Clinical Pipeline by Company, Indication & Phase
- Global HIV Vaccine Clinical Pipeline: 65 Vaccines
1. INTRODUCTION TO HUMAN IMMUNODEFICIENCY VIRUS (HIV) VACCINES
1.1 Overview
1.2 Antiquity of HIV Vaccine
2. NEED FOR THE DEVELOPMENT OF HIV VACCINE
3. PRIMER OF HIV INSIDE THE BODY
3.1 Inclusion of HIV Virus into the System
3.2 Interaction of HIV with Host
3.3 Eradication of HIV Virus
4. HIV VACCINE DEVELOPMENT PROCESS
4.1 Introduction
4.1.1 Classification of HIV Virus
4.1.2 Structure of HIV Virus
4.2 HIV Vaccine Construct Methodologies
4.2.1 Live Attenuated Vaccine
4.2.2 Synthetic Peptide Vaccines
4.2.3 Inactivated Vaccines
4.2.4 DNA Vaccine
4.2.5 Recombinant Vector Vaccine
5. MODIFIED APPROACHES FOR HIV VACCINE DEVELOPMENT
5.1 HIV Vaccine Expansion by Computer Aided Drug Design
5.2 Genetic Variety Attentions for Vaccine Design
5.3 Virus like Particles Approach for the HIV Vaccine Production
5.4 T-cell based Approach for HIV Vaccine
6. PROPHYLACTIC & THERAPEUTIC HIV VACCINE
6.1 Prophylactic HIV Vaccine
6.1.1 Pre Exposure Prophylaxis
6.1.2 Post Exposure Prophylaxis (PEP)
6.2 Therapeutic HIV Vaccine
7. HIV DRUGS TAXONOMY & RESISTANCE
7.1 Categorization of the Drugs
7.1.1 Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs)
7.1.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
7.1.3 Protease Inhibitors
7.1.4 Fusion Inhibitors
7.2 Contrivance of HIV Drug Resistance
7.2.1 Resistance to Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
7.2.2 Resistance to Non-Nucleoside Reverse Transcriptase Inhibitors
7.2.3 Resistance to Protease Inhibitors
7.2.4 Resistance to Fusion Inhibitors
8. DECISIVE FACTORS FOR COMMERCIALIZATION OF HIV VACCINES
8.1 Efficacy
8.2 Controlled Transmission
8.3 Relapse
8.4 Economical
8.5 Manufacturing Scalability
9. GLOBAL HIV VACCINE MARKET OUTLOOK
9.1 Overview
9.2 Current Market Scenario
9.3 Incidence & Prevalence
9.4 Funding Scenario for HIV Vaccine
10. GLOBAL HIV VACCINE CLINICAL PIPELINE OVERVIEW
11. GLOBAL HIV VACCINE MARKET DYNAMICS
11.1 Favorable Market Parameters
11.2 Commercialization Challenges
12. GLOBAL HIV VACCINE MARKET FUTURE OUTLOOK
13. GLOBAL HIV VACCINE CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
13.1 Research
13.2 Preclinical
13.3 Clinical
13.4 Phase-I
13.5 Phase-I/II
13.6 Phase-II
13.7 Phase-III
13.8 Preregistration
14. COMPETITIVE LANDSCAPE
14.1 AlphaVax
14.2 Antigen Express
14.3 Argo Therapeutics
14.4 Bionor Pharmaceuticals
14.5 Celldex Therapeutics
14.6 FIT Biotech
14.7 Crucell Pharmaceutical
14.8 GeneCure
14.9 Genetic Immunity
14.10 GenVec
14.11 GeoVax Labs
14.12 Glaxo Smithkline
14.13 Immune Response BioPharma
14.14 Inovio Pharmaceuticals
14.15 Novartis
14.16 Oncolys Biopharma
14.17 PaxVax
14.18 Profectus Biosciences
14.19 Sanofi
14.20 TVAX Biomedical
1.1 Overview
1.2 Antiquity of HIV Vaccine
2. NEED FOR THE DEVELOPMENT OF HIV VACCINE
3. PRIMER OF HIV INSIDE THE BODY
3.1 Inclusion of HIV Virus into the System
3.2 Interaction of HIV with Host
3.3 Eradication of HIV Virus
4. HIV VACCINE DEVELOPMENT PROCESS
4.1 Introduction
4.1.1 Classification of HIV Virus
4.1.2 Structure of HIV Virus
4.2 HIV Vaccine Construct Methodologies
4.2.1 Live Attenuated Vaccine
4.2.2 Synthetic Peptide Vaccines
4.2.3 Inactivated Vaccines
4.2.4 DNA Vaccine
4.2.5 Recombinant Vector Vaccine
5. MODIFIED APPROACHES FOR HIV VACCINE DEVELOPMENT
5.1 HIV Vaccine Expansion by Computer Aided Drug Design
5.2 Genetic Variety Attentions for Vaccine Design
5.3 Virus like Particles Approach for the HIV Vaccine Production
5.4 T-cell based Approach for HIV Vaccine
6. PROPHYLACTIC & THERAPEUTIC HIV VACCINE
6.1 Prophylactic HIV Vaccine
6.1.1 Pre Exposure Prophylaxis
6.1.2 Post Exposure Prophylaxis (PEP)
6.2 Therapeutic HIV Vaccine
7. HIV DRUGS TAXONOMY & RESISTANCE
7.1 Categorization of the Drugs
7.1.1 Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs)
7.1.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
7.1.3 Protease Inhibitors
7.1.4 Fusion Inhibitors
7.2 Contrivance of HIV Drug Resistance
7.2.1 Resistance to Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
7.2.2 Resistance to Non-Nucleoside Reverse Transcriptase Inhibitors
7.2.3 Resistance to Protease Inhibitors
7.2.4 Resistance to Fusion Inhibitors
8. DECISIVE FACTORS FOR COMMERCIALIZATION OF HIV VACCINES
8.1 Efficacy
8.2 Controlled Transmission
8.3 Relapse
8.4 Economical
8.5 Manufacturing Scalability
9. GLOBAL HIV VACCINE MARKET OUTLOOK
9.1 Overview
9.2 Current Market Scenario
9.3 Incidence & Prevalence
9.4 Funding Scenario for HIV Vaccine
10. GLOBAL HIV VACCINE CLINICAL PIPELINE OVERVIEW
11. GLOBAL HIV VACCINE MARKET DYNAMICS
11.1 Favorable Market Parameters
11.2 Commercialization Challenges
12. GLOBAL HIV VACCINE MARKET FUTURE OUTLOOK
13. GLOBAL HIV VACCINE CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
13.1 Research
13.2 Preclinical
13.3 Clinical
13.4 Phase-I
13.5 Phase-I/II
13.6 Phase-II
13.7 Phase-III
13.8 Preregistration
14. COMPETITIVE LANDSCAPE
14.1 AlphaVax
14.2 Antigen Express
14.3 Argo Therapeutics
14.4 Bionor Pharmaceuticals
14.5 Celldex Therapeutics
14.6 FIT Biotech
14.7 Crucell Pharmaceutical
14.8 GeneCure
14.9 Genetic Immunity
14.10 GenVec
14.11 GeoVax Labs
14.12 Glaxo Smithkline
14.13 Immune Response BioPharma
14.14 Inovio Pharmaceuticals
14.15 Novartis
14.16 Oncolys Biopharma
14.17 PaxVax
14.18 Profectus Biosciences
14.19 Sanofi
14.20 TVAX Biomedical
LIST OF FIGURES
Figure 1-1: Stages of HIV Infection
Figure 1-2: History of HIV
Figure 3-1: Modes of Transmission of HIV Virus into the System
Figure 3-2: Life Cycle of HIV Virus inside the Host Cell
Figure 4-1: Structure of HIV Virus
Figure 4-2: Approaches to Design an AIDS Vaccine
Figure 5-1: Modified Approaches for HIV Vaccine Development
Figure 7-1: Categories of Antiretroviral Drugs
Figure 7-2: Mechanism of Resistance to Nucleoside Reverse Transcriptase Inhibitors
Figure 7-3: Usage of Resistance to Non-Nucleoside Reverse Transcriptase Inhibitor
Figure 7-4: Resistance to Protease Inhibitors
Figure 7-5: Resistance to Fusion Inhibitors
Figure 8-1: Requirements for Successful Commercialization of HIV Vaccines
Figure 9-1: Global HIV/AIDS Therapeutics Market (US$ Billion), 2012-2022
Figure 9-2: Global - Truvada Sales (US$ Million), 2011-2015
Figure 9-3: Global – Atripla Sales (US$ Million), 2011-2015
Figure 9-4: Global – Prezista Sales (US$ Million), 2011-2015
Figure 9-5: Global – Complera/Eviplera Sales (US$ Million), 2011-2015
Figure 9-6: Global – Sustiva Sales (US$ Million), 2011-2015
Figure 9-7: Global – Sustiva Sales (US$ Million), 2011-2015
Figure 9-8: Global – Viread Sales (US$ Million), 2011-2015
Figure 9-9: Global – Epzicom Sales (US$ Million), 2011-2015
Figure 9-10: Global – Kaletra Sales (US$ Million), 2011-2015
Figure 9-11: Global – Combivir Sales (US$ Million), 2011-2015
Figure 9-12: Global - HIV Incidence (Million), 2015
Figure 9-13: Global - People Living with HIV (Million), 2011-2015
Figure 9-14: Global – New HIV Infections (Million), 2011-2015
Figure 9-15: Global –HIV Deaths (Million), 2011-2015
Figure 9-16: Global – People Living with HIV On Antiretroviral Therapy (Million), 2011-2015
Figure 9-17: US – HIV Incidence (Million), 2015
Figure 9-18: Asia Pacific-HIV Incidence (Million), 2015
Figure 9-19: India - HIV Incidence (Million), 2015
Figure 9-20: Europe - HIV Incidence (Million), 2015
Figure 9-21: UK - HIV Incidence (Millions), 2015
Figure 9-22: South Africa - HIV Incidence (Million), 2015
Figure 9-23: Global - HIV prevention R&D Investments by Sector, 2015
Figure 9-24: US - Public Sector & Other Investments in HIV prevention R&D (%), 2011 to 2015
Figure 9-25: US - Public Sector Investments in HIV Prevention R&D by Technology (%), 2011 to 2015
Figure 9-26: Europe - Public Sector & Other Investments in HIV prevention R&D (%), 2011 to 2015
Figure 9-27: Europe - Public Sector Investments in HIV Prevention R&D by Technology (%), 2011 to 2015
Figure 9-28: Global - Investments in R&D Prevention by Top Philanthropic Funders (US$ Million)
Figure 9-29: Top Public Sector Investing in HIV Prevention R&D, 2012–2015 (US$ Million)
Figure 9-30: HIV Vaccines by Country (%), 2014
Figure 9-31: Philanthropic Sector Spending on HIV Vaccines by Clinical Research Phase (%)
Figure 10-1: Global HIV - Vaccine Pipeline by Phase (%), 2016 to 2022
Figure 10-2: Global HIV - Vaccine Pipeline by Phase (Numbers), 2016 to 2022
Figure 10-3: Global HIV - Vaccine Drugs Discontinued & Suspended in Clinical Pipeline by Phase (%), 2016 to 2022
Figure 10-4: Global HIV - Vaccine Drugs Discontinued & Suspended in Clinical Pipeline by Phase (Numbers), 2016 to 2022
Figure 11-1: Driving Forces of HIV Vaccine Market
Figure 11-2: Challenges to the HIV Vaccine Development
Figure 14-1: AlphaVax Clinical Pipeline
Figure 14-2: Bionor Pharma Clinical Pipeline
Figure 14-3: Profectus BioSciences Clinical Pipeline
Figure 14-4: TVAX Biomedical Clinical Pipeline
Figure 1-1: Stages of HIV Infection
Figure 1-2: History of HIV
Figure 3-1: Modes of Transmission of HIV Virus into the System
Figure 3-2: Life Cycle of HIV Virus inside the Host Cell
Figure 4-1: Structure of HIV Virus
Figure 4-2: Approaches to Design an AIDS Vaccine
Figure 5-1: Modified Approaches for HIV Vaccine Development
Figure 7-1: Categories of Antiretroviral Drugs
Figure 7-2: Mechanism of Resistance to Nucleoside Reverse Transcriptase Inhibitors
Figure 7-3: Usage of Resistance to Non-Nucleoside Reverse Transcriptase Inhibitor
Figure 7-4: Resistance to Protease Inhibitors
Figure 7-5: Resistance to Fusion Inhibitors
Figure 8-1: Requirements for Successful Commercialization of HIV Vaccines
Figure 9-1: Global HIV/AIDS Therapeutics Market (US$ Billion), 2012-2022
Figure 9-2: Global - Truvada Sales (US$ Million), 2011-2015
Figure 9-3: Global – Atripla Sales (US$ Million), 2011-2015
Figure 9-4: Global – Prezista Sales (US$ Million), 2011-2015
Figure 9-5: Global – Complera/Eviplera Sales (US$ Million), 2011-2015
Figure 9-6: Global – Sustiva Sales (US$ Million), 2011-2015
Figure 9-7: Global – Sustiva Sales (US$ Million), 2011-2015
Figure 9-8: Global – Viread Sales (US$ Million), 2011-2015
Figure 9-9: Global – Epzicom Sales (US$ Million), 2011-2015
Figure 9-10: Global – Kaletra Sales (US$ Million), 2011-2015
Figure 9-11: Global – Combivir Sales (US$ Million), 2011-2015
Figure 9-12: Global - HIV Incidence (Million), 2015
Figure 9-13: Global - People Living with HIV (Million), 2011-2015
Figure 9-14: Global – New HIV Infections (Million), 2011-2015
Figure 9-15: Global –HIV Deaths (Million), 2011-2015
Figure 9-16: Global – People Living with HIV On Antiretroviral Therapy (Million), 2011-2015
Figure 9-17: US – HIV Incidence (Million), 2015
Figure 9-18: Asia Pacific-HIV Incidence (Million), 2015
Figure 9-19: India - HIV Incidence (Million), 2015
Figure 9-20: Europe - HIV Incidence (Million), 2015
Figure 9-21: UK - HIV Incidence (Millions), 2015
Figure 9-22: South Africa - HIV Incidence (Million), 2015
Figure 9-23: Global - HIV prevention R&D Investments by Sector, 2015
Figure 9-24: US - Public Sector & Other Investments in HIV prevention R&D (%), 2011 to 2015
Figure 9-25: US - Public Sector Investments in HIV Prevention R&D by Technology (%), 2011 to 2015
Figure 9-26: Europe - Public Sector & Other Investments in HIV prevention R&D (%), 2011 to 2015
Figure 9-27: Europe - Public Sector Investments in HIV Prevention R&D by Technology (%), 2011 to 2015
Figure 9-28: Global - Investments in R&D Prevention by Top Philanthropic Funders (US$ Million)
Figure 9-29: Top Public Sector Investing in HIV Prevention R&D, 2012–2015 (US$ Million)
Figure 9-30: HIV Vaccines by Country (%), 2014
Figure 9-31: Philanthropic Sector Spending on HIV Vaccines by Clinical Research Phase (%)
Figure 10-1: Global HIV - Vaccine Pipeline by Phase (%), 2016 to 2022
Figure 10-2: Global HIV - Vaccine Pipeline by Phase (Numbers), 2016 to 2022
Figure 10-3: Global HIV - Vaccine Drugs Discontinued & Suspended in Clinical Pipeline by Phase (%), 2016 to 2022
Figure 10-4: Global HIV - Vaccine Drugs Discontinued & Suspended in Clinical Pipeline by Phase (Numbers), 2016 to 2022
Figure 11-1: Driving Forces of HIV Vaccine Market
Figure 11-2: Challenges to the HIV Vaccine Development
Figure 14-1: AlphaVax Clinical Pipeline
Figure 14-2: Bionor Pharma Clinical Pipeline
Figure 14-3: Profectus BioSciences Clinical Pipeline
Figure 14-4: TVAX Biomedical Clinical Pipeline
